Latest Acute eosinophilic leukemia Stories
Scientists at Albert Einstein College of Medicine of Yeshiva University have made a discovery involving mice and humans that could mean that people with acute myeloid leukemia (AML), a rare and usually fatal cancer, are a step closer to new treatment options.
Melbourne researchers have discovered that acute myeloid leukemia (AML), an aggressive blood cancer with poor prognosis, may be susceptible to medications that target a protein called Mcl-1.
Older people with acute myeloid leukemia and normal looking chromosomes in their cancer cells have a higher risk of recurrence if they have mutations in a gene called ASXL1.
A new potential leukemia therapy targets only cancer cells, while leaving healthy cells alone.
Blacks and Hispanics have fewer cases of acute leukemia compared to whites but they die at a substantially higher rate.
The prognosis for nearly three-quarters of elderly patients on intensive chemotherapy for acute myeloid leukemia (AML) is poor, with a median survival of less than six months.
Findings provide clues for treating thousands of patients diagnosed each year.